Posted on September 2, 2011 by Sitemaster
There has been considerable interest in yesterday?s news item about JX-594 and its potential applicability to the treatment of prostate cancer, so we have done a little more homework.
At this time, it appears that the primary future focus on clinical research into the utility of JX-594 will be in the management of liver cancer (hepatocellular carcinoma) and colorectal cancer. (For more information, please see this link to the ClinicalTrials.gov web site.) However, it is worth noting that a small trial of JX-594 was completed some time ago in patients with malignant and unresectable melanoma.
We assume that like most small biotech companies, Jennerex has to manage its financial resources with care in order to seek an appropriate ?return on its investment.?
We may have to be patient before it can be learned whether JX-594 and similar agents have significant activity and clinical value in the treatment of prostate cancer ? but the potential would seem to exist.
Additional background on JX-594 is available on the Jennerex Biotherapeutics web site.
Like this:
Be the first to like this post.
Filed under: Drugs in development Tagged: | Jennerex, JX-594, viral therapy
Source: http://prostatecancerinfolink.net/2011/09/02/jx-594-and-prostate-cancer-some-follow-up/
kidney stones stevie ray vaughan stevie ray vaughan nascar schedule nick jr weather boston hallelujah lyrics
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.